SNDX — Syndax Pharmaceuticals Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1395937 ·
Last close
$9.20
Market Cap
$828.26M
52W High
$25.59
52W Low
$9.03
ADV30
3,590,557
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 83,298,000 69,302,000 -41,895,000 -49,433,000 692,671,000 135,941,000 709,851,000
Jun 2026 72,788,000 69,580,000 -39,995,000 -49,363,000 703,652,000 336,477,000 688,553,000
Mar 2026 64,864,000 62,231,000 -34,202,000 -42,673,000 472,668,000 130,893,000 431,046,000
Dec 2025 68,728,000 66,022,000 -62,548,000 -68,014,000 529,706,000 134,930,000 465,076,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-177,359,000
Investing CF
$-73,417,000
Financing CF
$269,794,000
CapEx
$-56,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.36
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,648,049,000
Inventory
$39,376,000
Receivables
$79,782,000
ST Investments
$291,163,000
EBIT TTM
$-162,390,000
Pretax Income TTM
$-209,483,000
Interest Exp TTM
$47,093,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$289,678,016
EBITDA
$-178,622,000
Free Cash Flow
$-113,034,128
Enterprise Value
$1,011,027,584
Total Cash
$437,256,992
Total Debt
$589,414,976
Shares Out
90,028,256
Trailing EPS
$-2.37
Book Value
$-0.19
ROE
-426.4%
ROA
-17.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 172,352,000 -273,084,000 -285,422,000 529,706,000 465,076,000 64,630,000 -322,980,000
Dec 2024 23,680,000 -339,672,000 -318,758,000 724,816,000 436,692,000 288,124,000 -274,903,000
Dec 2023 0 -229,954,000 -209,360,000 612,880,000 58,684,000 554,196,000 -160,601,000
Dec 2022 0 -151,757,000 -149,338,000 497,236,000 29,787,000 467,449,000 -133,675,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$252,004,000
NetIncome TTM
$-220,765,000
OpCashFlow TTM
—
Assets (Latest)
$703,652,000
Forward EPS
$-0.83

Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $17.00 · spot: $8.56 · call volume: 94 · put volume: 1,560
Expected Move to 2028-01-21: ±$4.56 (53.27%) — implied range $4.00 – $13.12 · ATM straddle on $8.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ORIC Oric Pharmaceuticals, Inc. $829.22M $8.00 —
CTY CITY THERAPEUTICS, INC. $846.44M $17.50 —
RIGL RIGEL PHARMACEUTICALS INC $808.18M $42.92 —
IRWD IRONWOOD PHARMACEUTICALS INC $806.23M $4.87 —
PHAR Pharming Group N.V. $853.58M $12.06 —

News headlines (Yahoo Finance, 1h cache)

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2026-11-09 22:26 · Yahoo
Why Is Syndax Pharmaceuticals (SNDX) Drawing So Much ASH 2026 Attention?
2026-11-05 22:14 · Yahoo
Syndax Pharmaceuticals Inc (SNDX) (Q3 2026) Earnings Call Highlights: Revenue Surges 82% as ...
2026-11-05 05:01 · Yahoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-11-04 21:01 · Yahoo
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
2026-11-04 14:01 · Yahoo
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
2026-11-04 14:00 · Yahoo
Syndax Pharmaceuticals Stock Gains Focus After Revenue Growth And Pipeline Progress
2026-11-04 00:25 · Yahoo
Syndax Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-03 13:30 · Yahoo
Syndax Pharmaceuticals (SNDX) Stock May Be Rich After Revuforj Award Win
2026-11-03 08:08 · Yahoo
Syndax Pharmaceuticals (SNDX) Missed On Q3 Results, Is The 65% Undervaluation Case Still Intact?
2026-11-03 06:16 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.